-
Posted by
Two Blokes Jul 11 -
Filed in
Stock
-
2 views
Certara is a leader in Model-Informed Drug Development (MIDD), offering essential software and services that reduce drug development costs and time. The company's diversified software portfolio and growing client base drive consistent revenue growth, with software revenue accelerating thanks to the Chemaxon acquisition. Certara's financials are strong, with stable cash flow, a healthy balance sheet, and a price-to-book ratio below the sector average, suggesting undervaluation.
